Sign In

7.4 : Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.

Although all competitive neuromuscular blockers are designed to produce desirable pharmacological actions, they can also have adverse effects mediated by histamine or autonomic receptors. Drugs like tubocurarine and atracurium lead to histamine release into the systemic circulation. Histamine can cause a fall in blood pressure or hypotension. Pancuronium increases the heart rate and cardiac output. The release of larger doses of histamine can block autonomic ganglions, which affects cardiovascular functions, increasing the heart rate and blood pressure. Bradycardia occurs initially, followed by tachycardia. Prolonged administration of drugs like succinylcholine can result in cardiac arrhythmias and even cardiac arrest in some patients. Other patients may experience flushing, bronchospasm, and increased respiratory secretions.

Tags
Nondepolarizing Neuromuscular BlockersPharmacological ActionsMuscle Contraction InhibitionHistamine ReleaseCompetitive Neuromuscular BlockersAdverse EffectsTubocurarineAtracuriumHypotensionPancuroniumCardiac OutputBradycardiaTachycardiaSuccinylcholineCardiac Arrhythmias

From Chapter 7:

article

Now Playing

7.4 : Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Skeletal Muscle Relaxants

276 Views

article

7.1 : Neuromuscular Junction And Blockade

Skeletal Muscle Relaxants

1.9K Views

article

7.2 : Classification of Skeletal Muscle Relaxants

Skeletal Muscle Relaxants

2.1K Views

article

7.3 : Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Skeletal Muscle Relaxants

972 Views

article

7.5 : Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

Skeletal Muscle Relaxants

356 Views

article

7.6 : Depolarizing Blockers: Mechanism of Action

Skeletal Muscle Relaxants

839 Views

article

7.7 : Depolarizing Blockers: Pharmocokinetics

Skeletal Muscle Relaxants

228 Views

article

7.8 : Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Skeletal Muscle Relaxants

433 Views

article

7.9 : Skeletal Muscle Relaxants: Adverse Effects

Skeletal Muscle Relaxants

251 Views

article

7.10 : Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal Muscle Relaxants

380 Views

article

7.11 : Spasmolytic Agents: Chemical Classification

Skeletal Muscle Relaxants

765 Views

article

7.12 : Peripherally and Centrally Acting Muscle Relaxants: A Comparison

Skeletal Muscle Relaxants

2.7K Views

article

7.13 : Centrally Acting Muscle Relaxants: Therapeutic Uses

Skeletal Muscle Relaxants

395 Views

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved